Author: "Fattoruso, S." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Fattoruso, S."' showing total 29 results

Start Over Author "Fattoruso, S."

29 results on '"Fattoruso, S."'

1. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.

Author: Fattoruso, S. I. S., De Luca, R., Grassadonia, A., Evola, S., Salvato, A., Addeo, R., and Cicero, G.
Subjects: DOXORUBICIN, CYCLOPHOSPHAMIDE, BREAST metastasis, CARDIOTOXICITY, HEALTH of older women
Abstract: Background. The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment. Methods. 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1. Results. The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6-18.8) and median progression free survival was 5.8 months (95%CI:4.4-8.6). Hematologic toxicity with neutropenia was the most frequent adverse event, but the treatment was well tolerated maintained a manageable cardiotoxicity. Conclusion. Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and decreases cardiotoxicity. [ABSTRACT FROM AUTHOR]
Published: 2022
Full Text: View/download PDF

2. Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy

Author: Adamo, M., Alessi, D., Aletta, P., Amodio, R., Andreone, S., Angelin, T., Anghinoni, E., Annulli, M., Arciprete, C., Artioli, M., Autelitano, M., Baili, P., Balducci, C., Baracco, M., Baracco, S., Battisti, W., Bella, F., Bellatalla, C., Bellini, A., Belluardo, C., Benatti, P., Benedetto, G., Benfatto, L., Bernazza, E., Bianconi, F., Biavati, P., Bidoli, E., Birri, S., Bizzoco, S., Bonelli, L., Bonini, A., Borciani, E., Bordini, M., Bovo, E., Bozzani, F., Braghiroli, B., Brucculeri, M., Brunori, V., Bucalo, G., Bucchi, L., Bugliarello, E., Bulatko, A., Busco, S., Busso, P., Buzzoni, C., Calabrese, A., Calabretta, L., Caldarella, A., Candela, G., Cannone, G., Canu, L., Caparelli, M., Capocaccia, R., Cappelletti, M., Caprara, L., Carboni, D., Carletti, N., Caroli, S., Cascio, M., Cascone, G., Casella, C., Castaing, M., Cavalieri, D., L, Cecconami, L., Celesia, M., Cena, T., Cercato, M., Cesaraccio, R., Chiesa, R., Cirilli, C., Cocchioni, M., Codazzi, T., Cogno, R., Colamartini, A., Colanino, Z., A, Cometti, I., Contiero, P., Contrino, M., Corbinelli, A., Cordaro, C., Corti, M., Costa, A., Costarelli, D., Coviello, V., Crapanzano, G., Cremone, L., Crocetti, E., Cuccaro, F., Curatella, S., Cusimano, R., D Alò, D., Dal, C., Dal, T., Cin, A., Dal, M., Davini, C., Dottori, D., De, M., Angelis, R., Santis, D., De, E., Valiere, E., Dei, T., Demurtas, G., Devigili, E., Felice, D., Di, E., Grazia, L., Gregorio, D., Di, C., Norcia, R., Prima, D., Dinaro, Y., Distefano, R., Doa, N., Domati, F., Fabiano, S., Facchinelli, G., Falcini, F., Falk, M., Fanetti, A., Fattoruso, S., Federico, M., Ferrari, F., Ferrari, L., Ferretti, S., Fidelbo, M., Filipazzi, L., Fiore, A., Fiori, G., Foca, F., Forgiarini, O., Foschi, R., Francisci, S., Frasca, G., Frassoldi, E., Fusco, M., Gada, D., Garrone, E., Gasparotti, C., Gatta, G., Gatti, L., Gaudiano, C., Gennaro, V., Gentilini, M., Gerevini, C., Ghilardi, S., Ghisleni, S., Giacomin, A., Giavazzi, L., Gigli, A., Gilardi, F., Giorgetti, S., Giorgi, R., P, Giubelli, C., Giuliani, O., Giurdanella, M., Gola, G., Goldoni, C., Golizia, M., Greco, A., Guarda, L., Guttadauro, A., Guzzinati, S., Iachetta, F., Iannelli, A., Ieni, A., Intrieri, T., Kaleci, S., Rosa, L., F, Lando, C., Lavecchia, A., Lazzarato, F., Rose, L., Leone, A., Leone, R., Lonati, F., Lucchi, S., Luminari, S., Macci, L., Macerata, V., Madeddu, A., Maffei, S., Maghini, A., Magnani, C., Magnani, G., Magoni, M., Mallone, S., Mameli, G., Mancini, S., Mancuso, P., Mangone, L., Manneschi, G., Mannino, R., Mannino, S., Marani, E., Marchesi, C., Mariani, F., Martorana, C., Marzola, L., Maspero, S., Maule, M., Mazzei, A., Mazzoleni, G., Mazzucco, G., Melcarne, A., Merletti, F., Merlo, E., Michiara, M., Migliari, E., Minerba, S., Minicuzzi, A., Mizzi, M., Monetti, D., Morana, G., Moroni, E., Mosso, M., Muni, A., Mura, F., Natali, M., Negrino, L., Nemcova, L., Nicita, C., Ocello, C., Pala, F., Palumbo, M., Panciroli, E., Panico, M., Pannozzo, F., Pascucci, C., Pasolini, A., Pastore, G., Patriarca, S., Pedroni, M., Perrotta, C., Pesce, P., Petrinelli, A., Petrucci, C., Pezzarossi, A., Pezzuto, L., Piffer, S., Pinon, M., Antonio Pinto, Pintori, N., Pirani, M., Pirino, D., Pironi, V., Ponz, D., Leon, M., Prandi, R., Prazzoli, R., Puleio, M., Puppo, A., Quarta, F., Quattrocchi, M., Ramazzotti, V., Rashid, I., Ravaioli, A., Ravazzolo, B., Ravegnani, M., Reggiani Bonetti, L., Ricci, P., Rinaldi, E., Rizzello, R., Rognoni, M., Rollo, P., Roncaglia, F., Roncucci, L., Rosano, A., Rossi, F., Rossi, G., Rossi, M., Rossi, S., Rossini, S., Rosso, S., Rudisi, G., Ruggeri, M., Russo, A., Russo, M., Sacchettini, C., Sacchetto, L., Sacco, G., Sacerdote, C., Salvatore, S., Salvi, O., Sampietro, G., Santucci, C., Scheibel, M., Sciacca, S., Sciacchitano, C., Sciacchitano, S., Scuderi, T., Sechi, O., Seghini, P., Senatore, G., Serafini, G., Serraino, D., Sgargi, P., Sini, G., Sobrato, I., Soddu, M., Solimene, C., Spano, F., Spata, E., Sperduti, I., Spinosa, S., Staiti, R., Stocco, C., Stracci, F., Sunseri, R., Sutera, S., Tagliabue, G., Tamburo, L., Tamburrino, S., Taranto, V., Terracini, B., Tisano, F., Tittarelli, A., Tognazzo, S., Torrisi, A., Traina, A., Trama, A., Trapani, C., Tschugguel, B., Tumino, R., Usala, M., Vacirca, S., Valerio, O., Valla, K., Varvarà, M., Vasquez, E., Vassante, B., Vattiato, R., Vercelli, M., Vercellino, P., Vicentini, M., Villa, M., Virdone, S., Francesco Vitale, Vitale, M., Vitali, B., Vitali, M., Vitarelli, S., Zanchi, A., Zanetti, R., Zani, G., Zanier, L., Zappa, M., Zarcone, M., Zevola, A., Zorzi, M., Zucchetto, A., Zucchi, A., Adamo, MS, Alessi, D, Aletta, P, Amodio, R, Andreone, S, Angelin, T, Anghinoni, E, Annulli, ML, Arciprete, C, Artioli, ME, Autelitano, M, Baili, P, Balducci, C, Baracco, M, Baracco, S, Battisti, W, Bella, F, Bellatalla, C, Bellini, A, Belluardo, C, Benatti, P, Benedetto, G, Benfatto, L, Bernazza, E, Bianconi, F, Biavati, P, Bidoli, E, Birri, S, Bizzoco, S, Bonelli, L, Bonini, A, Borciani, E, Bordini, M, Bovo, E, Bozzani, F, Braghiroli, B, Brucculeri, MA, Brunori, V, Bucalo, G, Bucchi, L, Bugliarello, E, Bulatko, A, Busco, S, Busso, P, Buzzoni, C, Calabrese, A, Calabretta, L, Caldarella, A, Candela, G, Cannone, G, Canu, L, Caparelli, M, Capocaccia, R, Cappelletti, M, Caprara, L, Carboni, D, Carletti, N, Caroli, S, Cascio, MA, Cascone, G, Casella, C, Castaing, M, Cavalieri, d'Oro, L, Cecconami, L, Celesia, MV, Cena, T, Cercato, MC, Cesaraccio, R, Chiesa, R, Cirilli, C, Cocchioni, M, Codazzi, T, Cogno, R, Colamartini, A, Colanino, Ziino, A, Cometti, I, Contiero, P, Contrino, ML, Corbinelli, A, Cordaro, C, Corti, M, Costa, A, Costarelli, D, Coviello, V, Crapanzano, G, Cremone, L, Crocetti, E, Cuccaro, F, Curatella, S, Cusimano, R, D'Alò, D, Dal, Cappello, T, Dal, Cin, A, Dal, Maso, L, Davini, C, De, Dottori, M, De, Angelis, R, De, Santis, E, De, Valiere, E, Dei, Tos, AP, Demurtas, G, Devigili, E, Di, Felice, E, di, Grazia, L, Di, Gregorio, C, di, Norcia, R, Di, Prima, A, Dinaro, Y, Distefano, R, Doa, N, Domati, F, Fabiano, S, Facchinelli, G, Falcini, F, Falk, M, Fanetti, AC, Fattoruso, S, Federico, M, Ferrari, F, Ferrari, L, Ferretti, S, Fidelbo, M, Filipazzi, L, Fiore, AR, Fiori, G, Foca, F, Forgiarini, O, Foschi, R, Francisci, S, Frasca, G, Frassoldi, E, Fusco, M, Gada, D, Garrone, E, Gasparotti, C, Gatta, G, Gatti, L, Gaudiano, C, Gennaro, V, Gentilini, MA, Gerevini, C, Ghilardi, S, Ghisleni, S, Giacomin, A, Giavazzi, L, Gigli, A, Gilardi, F, Giorgetti, S, Giorgi, Rossi, P, Giubelli, C, Giuliani, O, Giurdanella, MC, Gola, G, Goldoni, CA, Golizia, MG, Greco, A, Guarda, L, Guttadauro, A, Guzzinati, S, Iachetta, F, Iannelli, A, Ieni, A, Intrieri, T, Kaleci, S, La, Rosa, F, Lando, C, Lavecchia, AM, Lazzarato, F, Le, Rose, L, Leone, A, Leone, R, Lonati, F, Lucchi, S, Luminari, S, Macci, L, Macerata, V, Madeddu, A, Maffei, S, Maghini, A, Magnani, C, Magnani, G, Magoni, M, Mallone, S, Mameli, G, Mancini, S, Mancuso, P, Mangone, L, Manneschi, G, Mannino, R, Mannino, S, Marani, E, Marchesi, C, Mariani, F, Martorana, C, Marzola, L, Maspero, S, Maule, M, Mazzei, A, Mazzoleni, G, Mazzucco, G, Melcarne, A, Merletti, F, Merlo, E, Michiara, M, Migliari, E, Minerba, S, Minicuzzi, A, Mizzi, M, Monetti, D, Morana, G, Moroni, E, Mosso, ML, Muni, A, Mura, F, Natali, M, Negrino, L, Nemcova, L, Nicita, C, Ocello, C, Pala, F, Palumbo, M, Panciroli, E, Panico, M, Pannozzo, F, Pascucci, C, Pasolini, A, Pastore, G, Patriarca, S, Pedroni, M, Perrotta, C, Pesce, P, Petrinelli, AM, Petrucci, C, Pezzarossi, A, Pezzuto, L, Piffer, S, Pinon, M, Pinto, A, Pintori, N, Pirani, M, Pirino, D, Pironi, V, Ponz, de, Leon, M, Prandi, R, Prazzoli, R, Puleio, M, Puppo, A, Quarta, F, Quattrocchi, M, Ramazzotti, V, Rashid, I, Ravaioli, A, Ravazzolo, B, Ravegnani, M, Reggiani-Bonetti, L, Ricci, P, Rinaldi, E, Rizzello, R, Rognoni, M, Rollo, PC, Roncaglia, F, Roncucci, L, Rosano, A, Rossi, F, Rossi, G, Rossi, M, Rossi, S, Rossini, S, Rosso, S, Rudisi, G, Ruggeri, MG, Russo, AG, Russo, M, Sacchettini, C, Sacchetto, L, Sacco, G, Sacerdote, C, Salvatore, S, Salvi, O, Sampietro, G, Santucci, C, Scheibel, M, Sciacca, S, Sciacchitano, C, Sciacchitano, S, Scuderi, T, Sechi, O, Seghini, P, Senatore, G, Serafini, G, Serraino, D, Sgargi, P, Sini, GM, Sobrato, I, Soddu, M, Solimene, C, Spano, F, Spata, E, Sperduti, I, Spinosa, S, Staiti, R, Stocco, C, Stracci, F, Sunseri, R, Sutera, Sardo, A, Tagliabue, G, Tamburo, L, Tamburrino, S, Taranto, V, Terracini, B, Tisano, F, Tittarelli, A, Tognazzo, S, Torrisi, A, Traina, A, Trama, A, Trapani, C, Tschugguel, B, Tumino, R, Usala, M, Vacirca, S, Valerio, O, Valla, K, Varvarà, M, Vasquez, E, Vassante, B, Vattiato, R, Vercelli, M, Vercellino, PC, Vicentini, M, Villa, M, Virdone, S, Vitale, F, Vitale, MF, Vitali, B, Vitali, ME, Vitarelli, S, Zanchi, A, Zanetti, R, Zani, G, Zanier, L, Zappa, M, Zarcone, M, Zevola, A, Zorzi, M, Zucchetto, A, and Zucchi, A
Subjects: Aged, 80 and over, Male, Medicine (all), Aged, Female, Humans, Italy, Middle Aged, Neoplasms, Prevalence, Registries, Survival Rate, Socio-culturale, Settore MED/42 - Igiene Generale E Applicata, 80 and over, cancer prevalence, cancer incidence, cancer in Italy
Abstract: This Report intends to estimate the total number of people still alive in 2010 after cancer diagnosis in Italy, regardless of the time since diagnosis, and to project these estimates to 2015. This study is also aimed to estimate the number of already cured cancer patients, whose mortality rates have become undistinguishable from that of the general population of the same age and sex.The study took advantage of the information from the AIRTUM database, which included 29 Cancer Registries (covering 21 million people, 35% of the Italian population). A total of 1,624,533 cancer cases diagnosed between 1976 and 2009 contributed to the study. For each registry, the observed prevalence was calculated. Prevalence for lengths of time exceeding the maximum duration of the registration and of the complete prevalence were derived by applying an estimated correction factor, the completeness index. This index was estimated by means of statistical regression models using cancer incidence and survival data available in registries with 18 years of observation or more. For 50 types or combinations of neoplasms, complete prevalence was estimated at 1.1.2010 as an absolute number and as a proportion per 100,000 inhabitants by sex, age group, area of residence, and years since diagnosis. Projections of complete prevalence for 1.1.2015 were computed under the assumption of a linear trend of the complete prevalence observed until 2010. Validated mixture cure models were used to estimate: the cure fraction, that is the proportion of patients who, starting from the time of diagnosis, are expected to reach the same mortality rate of the general population; the conditional relative survival (CRS), that is the cumulative probability of surviving some additional years, given that patients already survived a certain number of years; the time to cure, that is the number of years necessary so that conditional survival in the following five years (5-year CRS) exceeds the conventional threshold of 95% (i.e., mortality rates in cancer patients become undistinguishable compared to those of the general population); the proportion of patients already cured, i.e., people alive since a number of years exceeding time to cure.As of 1.1.2010, it was estimated that 2,587,347 people were alive after a cancer diagnosis, corresponding to 4.4% of the Italian population. A relevant geographical heterogeneity emerged, with a prevalence above 5% in northern registries and below 4% in southern areas. Men were 45% of the total (1,154,289) and women 55% (1,433,058). In the population aged 75 years or more, the proportions of prevalent cases were 20% in males and 13% in females, 11% between 60 and 74 years of age in both sexes. Nearly 600,000 Italian women were alive after a breast cancer diagnosis (41% of all women with this neoplasm), followed by women with cancers of the colon rectum (12%), corpus uteri (7%), and thyroid (6%). In men, 26% of prevalent cases (295,624) were patients with prostate cancer, 16% with either bladder or colon rectum cancer. The projections for 1.1.2015 are of three million (3,036,741) people alive after a cancer diagnosis, 4.9% of the Italian population; with a 20% increase for males and 15% for females, compared to 2010. The cure fractions were heterogeneous according to cancer type and age. Estimates obtained as the sum of cure fractions for all cancer types showed that more than 60% of patients diagnosed below the age of 45 years will reach the same mortality rate of the general population. This proportion decreased with increasing age and it was30% for cancer diagnosed after the age of 74 years. It was observed that 60% of all prevalent cases (1,543,531 people or 2.6% of overall Italian population) had been diagnosed5 years earlier (long-term survivors). Time to cure (5-year CRS95%) was reached in10 years by patients with cancers of the stomach, colon rectum, pancreas, corpus and cervix uteri, brain, and Hodgkin lymphoma. Mortality rates similar to the ones reported by the general population were reached after approximately 20 years for breast and prostate cancer patients. Five-year CRS remained95% for25 years after cancer diagnosis in patients with liver and larynx cancers, non-Hodgkin lymphoma, myeloma, and leukaemia. Time to cure was reached by 27% (20% in men and 33% in women) of all people living after a cancer diagnosis, defined as already cured.The study showed a steady increase over time (nearly +3% per year) of prevalent cases in Italy. A quarter of Italian cancer patients alive in 2010 can be considered as already cured. The AIRTUM Report 2014 describes characteristics of cancer patients and former-patients for 50 cancer types or combinations by sex and age. This detailed information promotes the conduction of studies aimed at expanding the current knowledge on the quality of life of these patients during and after the active phase of treatments (prevalence according to health status), on the long-term effects of treatments (in particular for paediatric patients), on the cost profile of cancer patients, and on rare tumours. All these observations have a high potential impact on health planning, clinical practice, and, most of all, patients' perspective.
Published: 2014

3. ITALIAN CANCER FIGURES - REPORT 2015: The burden of rare cancers in Italy = I TUMORI IN ITALIA - RAPPORTO 2015: I tumori rari in Italia

Author: Busco, Susanna, Buzzoni, Carlotta, Mallone, Sandra, Trama, Annalisa, Castaing, Marine, Bella, Francesca, Amodio, Rosalba, Bizzoco, Sabrina, Cassetti, Tiziana, Cirilli, Claudia, Cusimano, Rosanna, De Angelis, Roberta, Fusco, Mario, Gatta, Gemma, Gennaro, Valerio, Giacomin, Adriano, Giorgi Rossi, Paolo, Mangone, Lucia, Mannino, Salvatore, Rossi, Silvia, Pierannunzio, Daniela, Tavilla, Andrea, Tognazzo, Sandro, Tumino, Rosario, Vicentini, Massimo, Vitale, Maria Francesca, Crocetti, Emanuele, Dal Maso, Luigino, Mazzoleni, G, Bulatko, A, Devigili, E, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Vittadello, F, Coviello, V, Cuccaro, F, Calabrese, A, Pinto, A, Cannone, G, Vitali, Me, Sampietro, G, Ghisleni, S, Giavazzi, L, Zanchi, A, Zucchi, A, Giacomin, A, Vercellino, Pc, Andreone, S, Fedele, M, Barale, A, Germinetti, F, Magoni, M, Zani, G, Salvi, O, Puleio, M, Gerevini, C, Adorni, A, Chiesa, R, Lonati, F, Tumino, R, Cascone, G, Frasca, G, Giurdanella, Mc, Martorana, C, Morana, G, Nicita, C, Rollo, Pc, Ruggeri, Mg, Spata, E, Vacirca, S, Sciacca, S, Sciacchitano, C, Fidelbo, M, Paderni, F, Benedetto, G, Vasquez, E, Bella, F, Calabretta, L, Castaing, M, Di Prima, A, Ieni, A, Leone, A, Pesce, P, Sciacchitano, S, Torrisi, A, Varvarà, M, Sutera Sardo, A, Mazzei, A, Lavecchia, Am, Mancuso, P, Nocera, V, Gola, G, Corti, M, Grandi, L, Caparelli, M, Mannino, S, Belluardo, C, Bizzoco, S, Davini, C, Lucchi, S, Villa, M, Anghinoni, E, Di Norcia, R, Ferretti, S, Biavati, P, Marzola, L, Migliari, E, Carletti, N, Petrucci, C, Brosio, F, Piccinni, L, Valente, N, Barchielli, A, Buzzoni, C, Caldarella, A, Corbinelli, A, Di Dia PP, Intrieri, T, Manneschi, G, Nemcova, L, Susini, N, Visoli, C, Zappa, M, Serraino, D, Angelin, T, Bidoli, E, Birri, S, Dal Maso, L, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Filiberti, Ra, Casella, C, Marani, E, Puppo, A, Celesia, Mv, Cogno, R, Garrone, E, Pannozzo, F, Busco, S, Rashid, I, Ramazzotti, V, Cercato, Mc, Natali, M, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, Tamburrino, S, Fattoruso, S, Valerio, O, Melcarne, A, Quarta, F, Golizia, Mg, Raho, Am, De Maria, V, Vitarelli, S, Ricci, P, Guarda, L, Gatti, L, Pironi, V, Pasolini, A, Bordini, M, Autelitano, M, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Russo, Ag, Quattrocchi, M, Distefano, R, Panciroli, E, Bellini, A, Pinon, M, Spinosa, S, Spagnoli, G, Goldoni, Ca, Valla, K, Braghiroli, B, Cirilli, C, Donini, M, Amendola, V, Cavalieri d'Oro, L, Rognoni, M, Le Rose, L, Merlo, E, Negrino, L, Pezzuto, L, Fusco, M, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, Mf, Usala, M, Pala, F, Sini, Gm, Pintori, N, Canu, L, Demurtas, G, Doa, N, Vitale, F, Cusimano, R, Traina, A, Guttadauro, A, Cascio, Ma, Mannino, R, Ravazzolo, B, Brucculeri, Ma, Rudisi, G, Adamo, Ms, Amodio, R, Costa, A, Zarcone, M, Sunseri, R, Bucalo, G, Trapani, C, Staiti, R, Michiara, M, Bozzani, F, Sgargi, P, Borciani, E, Seghini, P, Faccini, F, Prazzoli, R, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Sacchettini, C, Ferrari, F, Roncaglia, F, Vicentini, M, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Caiazzo, Al, Cavallo, R, Colavolpe, Af, D'Alessandro, A, Iannelli, A, Lombardo, C, Senatore, G, Sensi, F, Cesaraccio, R, Sechi, O, Pirino, D, Mura, F, Contrino, Ml, Madeddu, A, Tisano, F, Muni, A, Dinaro, Y, Mizzi, M, Sacco, G, Aletta, P, Ziino, Ac, Maspero, S, Fanetti, Ac, Moroni, E, Cometti, I, Annulli, Ml, Cecconami, L, Minerba, S, Minicuzzi, A, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Sacchetto, L, Candela, G, Scuderi, T, Crapanzano, G, Taranto, V, Piffer, S, Gentilini, Ma, Rizzello, R, Cappelletti, M, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, Am, Solimene, C, Bianconi, F, Brunori, V, Tagliabue, G, Contiero, P, Tittarelli, A, Fabiano, S, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, di Grazia, L, Ruzza, Mr, Dei Tos AP, Baracco, M, Baracco, S, Bovo, E, Dal Cin, A, Fiore, Ar, Greco, A, Guzzinati, S, Monetti, D, Rosano, A, Stocco, C, Tognazzo, S, Zorzi, M, Merletti, F, Magnani, C, Pastore, G, Terracini, B, Alessi, D, Cena, T, Lazzarato, F, Macerata, V, Maule, M, Mosso, Ml, Sacerdote, C, Cocchioni, M, Pascucci, C, Ponz de Leon, M, Domati, F, Rossi, G, Kaleci, S, Rossi, F, Benatti, P, Roncucci, L, Di Gregorio, C, Magnani, G, Pedroni, M, Maffei, S, Mariani, F, Reggiani-Bonetti, L, Gennaro, V, Benfatto, L, Lando, C, Mazzucco, G, Romanelli, A, Storchi, C, Sala, O, Gabbi, C, and Buzzoni, C.
Published: 2016

4. Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening [Caratteristiche dei tumori del colon retto diagnosticati in Italia nei primi anni Duemila. Dati dello studio IMPATTO sdelo screening colorettale]

Author: Zorzi, Manuel, Mangone, Lucia, Anghinoni, Emanuela, Baracco, Susanna, Borciani, Elisabetta, Caldarella, Adele, Falcini, Fabio, Fanetti, Anna Clara, Ferretti, Stefano, Rossi, Paolo Giorgi, Michiara, Maria, Randi, Giorgia, Stracci, Fabrizio, Vicentini, Massimo, Zucchetto, Antonella, Zappa, Marco, Giacomin, A., Azzoni, A., Baldazzi, P., Collina, N., Pandolfi, P., Biavati, P., Gualandi, G., Sciacca, S., Pesce, P., Torrisi, A., Sciacchitano, C., Fidelbo, M., Finarelli, A. C., Naldoni, C., De'Bianchi, P. Sassoli, Landi, P., Matarese, V., De Togni, A., Palmonari, C., Crocetti, E., Grazzini, G., Manneschi, G., Mantellini, P., Serraino, D., Bidoli, E., Taborelli, M., Gini, A., Virdone, S., Puppo, A., Casella, C., Celesia, M., Cogno, R., Marani, E., Bugliarello, E., Fattoruso, S., Tamburo, L., Tamburrino, S., Bellardini, P., Autelitano, M., Frammartino, B., Bisanti, L., Ghilardi, S., Leone, R., Corradini, R., De Girolamo, F., Valla, K., Palombino, R., Gigli, L., Spena, S. Russo, Vitale, M. F., Cascio, M. A., Mannino, R., Mazzucco, W., Mistretta, A., Ravazzolo, B., Sgarzi, P., Bozzani, F., Zatelli, M., Zurlini, C., Caruana, P., Seghini, P., Gatti, G., Prazzoli, R., Campari, C., Paterlini, L., Cassetti, T., Sassatelli, R., Imolesi, C., Casale, C., Serafini, M., Vattiato, R., Giuliani, O., Cesaraccio, R., Sechi, O., Budroni, M., Madeddu, A., Contrino, M. L., Ziino, A. Colanino, Russo, M., Tisano, F., Fanetti, A. C., Maspero, S., Moroni, E., Cometti, I., Gentilini, M., Piffer, S., De Pretis, G., Caciagli, P., Pertile, R., Bianconi, F., Bucchi, D., Galeotti, M. E., Malaspina, M., Greco, A., Fiore, A. R., Stocco, C. F., and Fedato, C.
Subjects: Colorectal cancer, Colorectal cancer screening, Italy, Epidemiology, Public Health, Environmental and Occupational Health, Environmental and Occupational Health, Socio-culturale, Public Health
Published: 2015

5. I TUMORI IN ITALIA - RAPPORTO 2013: Tumori multipli = ITALIAN CANCER FIGURES - REPORT 2013: Multiple tumours

Author: Adamo, Ms, Alessi, D, Aletta, P, Amodio, R, Andreone, S, Angelin, T, Anghinoni, E, Annulli, Ml, Antonini, S, Artioli, Me, Autelitano, M, Balducci, C, Balottari, P, Baracco, M, Battisti, W, Bella, F, Bellatalla, C, Belluardo, C, Benatti, P, Benedetto, G, Benfatto, L, Bernazza, E, Bianconi, F, Biavati, P, Bidoli, E, Birri, S, Bizzoco, S, Bonelli, L, Bonini, A, Borciani, E, Bovo, E, Bozzani, F, Bozzeda, A, Braghiroli, B, Brucculeri, Ma, Brunori, V, Bucalo, G, Bucchi, L, Bugliarello, E, Bulatko, A, Busco, S, Busso, P, Buzzoni, C, Calabretta, L, Caldarella, A, Candela, G, Canu, L, Cappelletti, M, Caprara, L, Carboni, D, Carletti, N, Caroli, S, Carone, S, Cascio, Ma, Cascone, G, Casella, C, Castaing, M, Cecconami, L, Celesia, Mv, Cena, T, Cercato, Mc, Cesaraccio, R, Chiesa, R, Cirilli, C, Civaschi, A, Cocchioni, Mario, Codazzi, T, Cogno, R, Colamartini, A, Colanino Ziino, A, Cometti, I, Contiero, P, Contrino, Ml, Corbinelli, A, Cordaro, C, Corti, M, Costa, A, Costarelli, D, Cremone, L, Crocetti, E, Curatella, S, Cusimano, R, D'Alò, D, D'Angelo, S, Dal Cappello, T, Dal Cin, A, Dal Maso, L, Dall'Acqua, M, Dalsasso, F, Davini, C, De Dottori, M, De Maria, V, De Santis, E, De Valiere, E, Dei Tos AP, Demurtas, G, Devigli, E, Di Felice, E, di Grazia, L, Di Gregorio, C, Di Prima, A, Distefano, R, Doa, N, Domati, F, Fabiano, S, Facchinelli, G, Falcini, F, Falk, M, Fanetti, Ac, Fattoruso, S, Federico, M, Ferrari, L, Ferretti, S, Fidelbo, M, Filipazzi, L, Fiore, Ar, Fiori, G, Foca, F, Forgiarini, O, Frasca, G, Frassoldi, E, Frizza, J, Fusco, M, Gada, D, Garrone, E, Gasparotti, C, Gatti, L, Gaudiano, C, Gennaro, V, Gentilini, M, Gerevini, C, Ghilardi, S, Ghisleni, S, Giacomin, A, Giavazzi, L, Gilardi, F, Giorgetti, S, Giubelli, C, Giuliani, O, Giurdanella, Mc, Gola, G, Goldoni, Ca, Golizia, Mg, Grandi, L, Greco, A, Guarda, L, Guttadauro, A, Guzzinati, S, Iachetta, F, Iannelli, A, Ieni, A, Intrieri, T, Kaleci, S, La Rosa, F, Lando, C, Lavecchia, Am, Lazzarato, F, Leone, A, Leone, R, Lonati, F, Lottero, B, Lucchi, S, Luminari, S, Macci, L, Macerata, V, Madeddu, A, Maffei, S, Maghini, A, Magnani, C, Magnani, G, Magoni, M, Mameli, G, Mancini, S, Mancuso, P, Mangone, L, Manneschi, G, Mannino, R, Mannino, S, Marani, E, Mariani, F, Martorana, C, Marzola, L, Maspero, S, Maule, M, Mazzei, A, Mazzoleni, G, Mazzucco, G, Melcarne, A, Merletti, F, Michiara, M, Migliari, E, Minerba, S, Minicuzzi, A, Mizzi, M, Monetti, D, Morana, G, Moroni, E, Mosso, Ml, Muni, A, Mura, F, Natali, M, Nemcova, L, Nicita, C, Ocello, C, Paci, E, Pala, F, Palumbo, M, Panico, M, Pannozzo, F, Pascucci, Cristiana, Pastore, G, Patriarca, S, Pedroni, M, Pellegri, C, Perrotta, C, Pesce, P, Petrinelli, Am, Petrucci, C, Pezzarossi, A, Piffer, S, Pintori, N, Pirani, M, Pirino, D, Pironi, V, Ponz de Leon, M, Prandi, R, Prazzoli, R, Preto, L, Puleio, M, Puppo, A, Quaglia, A, Quarta, F, Quattrocchi, M, Raho, Am, Ramazzotti, V, Rashid, I, Ravaioli, A, Ravazzolo, B, Ravegnani, M, Reggiani Bonetti, L, Ribaudo, M, Rinaldi, E, Ricci, P, Rizzello, R, Rollo, Pc, Roncucci, L, Rosano, A, Rossi, F, Rossi, G, Rossi, M, Rossini, S, Rosso, S, Rudisi, G, Ruggeri, Mg, Russo, Ag, Russo, M, Sacchettini, C, Sacco, G, Sacerdote, C, Salvatore, S, Salvi, O, Sampietro, G, Sandrini, M, Santucci, C, Scheibel, M, Schiacchitano, S, Sciacca, S, Sciacchitano, C, Scuderi, T, Sechi, O, Seghini, P, Senatore, G, Serafini, G, Serraino, D, Sgargi, P, Sigona, A, Sini, Gm, Sobrato, I, Soddu, M, Solimene, C, Spano, F, Spata, E, Sperduti, I, Staiti, R, Stocco, C, Stracci, F, Sunseri, R, Sardo, As, Tagliabue, G, Tamburo, L, Tamburrino, S, Tanzarella, M, Terracini, B, Tessandori, R, Tisano, F, Tittarelli, A, Tognazzo, S, Torrisi, A, Traina, A, Trapani, C, Tschugguel, B, Tumino, R, Usala, M, Vacirca, S, Valerio, O, Valla, K, Varvarà, M, Vasquez, E, Vassante, B, Vattiato, R, Vercelli, M, Vercellino, Pc, Vicentini, M, Villa, M, Vitale, F, Vitale, Mf, Vitali, B, Vitarelli, Susanna, Zanchi, A, Zanetti, R, Zani, G, Zanier, L, Zappa, M, Zarcone, M, Zevola, A, Zucchetto, A, and Zucchi, A.
Published: 2013

6. Evaluation of diagnostic investigations used in breast cancer patients resident in Latina province during three years follow up after diagnosis

Author: Busco, S., primary, Sperduti, I., additional, Pistillucci, G., additional, Cirino, C., additional, Salesi, N., additional, Sciacca, V., additional, Di Cocco, B., additional, Ciorra, A., additional, Di Palma, T., additional, Rossi, R., additional, Calabretta, F., additional, Cardillo, F., additional, Fattoruso, S., additional, Fiori, M., additional, Burchi, D., additional, Pannozzo, F., additional, Albertoni, F., additional, and Veltri, E., additional
Published: 2015
Full Text: View/download PDF

7. Italian cancer figures, report 2012: Cancer in children and adolescents

Author: Pisani, P, Buzzoni, C, Crocetti, E, Maso, L, Rondelli, R, Alessi, D, Aricò, M, Bidoli, E, Ferrari, A, Fusco, M, Gatta, G, Guzzinati, S, Jankovic, M, Locatelli, F, Maule, M, Mosso, M, Pastore, G, Pession, A, Rashid, I, Sacerdote, C, Terracini, B, Tognazzo, S, Trama, A, Ferretti, S, Porta, F, Mazzoleni, G, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Cappello, T, Giacomin, A, Vercellino, P, Andreone, S, Marzola, L, Migliari, E, Carletti, N, Nenci, I, Caldarella, A, Corbinelli, A, Intrieri, T, Manneschi, G, Nemcova, L, Ocello, C, Sacchettini, C, Zappa, M, Paci, E, Serraino, D, Angelin, T, Birri, S, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Vercelli, M, Orengo, M, Casella, C, Marani, E, Puppo, A, Celesia, M, Cogno, R, Levrieri, I, Manenti, S, Garrone, E, Quaglia, A, Pannozzo, F, Busco, S, Ramazzotti, V, Cercato, M, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Valerio, O, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, Tamburrino, S, Fattoruso, S, Bisanti, L, Autelitano, M, Cuccaro, F, Randi, G, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Federico, M, Artioli, M, Valla, K, Braghiroli, B, Cirilli, C, Luminari, S, Pirani, M, Ferrari, L, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, M, Michiara, M, Bozzani, F, Sgargi, P, Tumino, R, Rosa, M, Cascone, G, Frasca, G, Giurdanella, M, Martorana, C, Morana, G, Nicita, C, Rollo, P, Ruggeri, M, Sigona, A, Spata, E, Vacirca, S, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Pellegri, C, Vicentini, M, D'Angelo, S, Balottari, P, Romagna, R, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Tonelli, C, Amadori, M, Cremone, L, Iannelli, A, Senatore, G, Zevola, A, Sechi, O, Budroni, M, Cesaraccio, R, Pirino, D, Carboni, D, Fiori, G, Soddu, M, Mameli, G, Mura, F, Contrino, M, Madeddu, A, Tisano, F, Sciacca, S, Muni, A, Mizzi, M, Russo, M, Sacco, G, Aletta, P, Ziino, A, Tessandori, R, Fanetti, A, Maspero, S, Cecconami, L, Annulli, M, Moroni, E, Gonzalez, M, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Piffer, S, Rizzello, R, Gentilini, M, Cappelletti, M, Rosa, F, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, A, Solimene, C, Bianconi, F, Brunori, V, Crosignani, P, Tagliabue, G, Contiero, P, Preto, L, Tittarelli, A, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, Costa, E, Grazia, L, Zambon, P, Baracco, M, Bovo, E, Cin, A, Fiore, A, Greco, A, Monetti, D, Rosano, A, Stocco, C, Donato, F, Limina, R, Adorni, A, Andreis, P, Zani, G, Piovani, F, Salvi, O, Puleio, M, Vitarelli, S, Candela, G, Pappalardo, G, Scuderi, T, Lottero, B, Ribaudo, M, Ricci, P, Guarda, L, Gatti, L, Bozzeda, A, Dall'Acqua, M, Pironi, V, Sardo, A, Mazzei, A, Sirianni, N, Lavecchia, A, Mancuso, P, Vitale, F, Cusimano, R, Amodio, R, Guttadauro, A, Ravazzolo, B, Bucalo, G, Trapani, C, Sunseri, R, Cascio, M, Brucculeri, M, Adamo, M, Mannino, R, Mistretta, A, Costa, A, Rudisi, G, Gola, G, Corti, M, Prosperini, E, Grandi, L, Sciacchitano, S, Fidelbo, M, Benedetto, G, Vasquez, E, Torrisi, A, Pesce, P, Calabretta, L, Bella, F, Leone, A, Ieni, A, Varvarà, M, Castaing, M, Di Prima, A, Benedetto, A, Paderni, F, Usala, M, Pala, F, Sini, G, Pintori, N, Canu, L, Demurtas, G, Doa, N, Lazzarato, F, Magnani, C, Merletti, F, Sarcerdote, C, Macerata, V, de Leon, M, Domati, F, Rossi, G, Goldoni, C, Rossi, F, De Gaetani, C, Benatti, P, Roncucci, L, Di Gregorio, C, Pedroni, M, Pezzi, A, Maffei, S, Mariani, F, Borsi, E, Cocchioni, M, Pascucci, C, Gennaro, V, Lazzarotto, A, Benfatto, L, Mazzucco, G, Montanaro, F, Traina, A, Carruba, G, Dolcemascolo, C, Staiti, R, Zarcone, M, Bisogno, G, Cuttini, M, De Rosa, M, Haupt, R, Soresina, A, Valsecchi, M, Fagioli, F, Bona, G, Dini, G, Conter, V, Biondi, A, Zecca, M, Fedeli, F, Massimino, M, Nespoli, L, Roncarolo, M, Basso, G, Cesaro, S, Memo, L, Bellettato, M, Tamaro, P, Mascarin, M, Rosolen, A, Izzi, G, Paolucci, P, Borgna Pignatti, C, Vecchi, V, Abate, M, D'Ambrosio, A, Favre, C, Caniglia, M, Pierani, P, Felici, L, Visani, G, Fioritoni, G, Foà, R, Riccardi, R, Frega, G, Clerico, A, Casale, F, Poggi, V, Amendola, G, Filosa, A, Ladogana, S, Presta, G, Tornesello, A, De Mattia, D, Consarino, C, Nobile, F, Sperlì, D, D'Angelo, P, Marino, S, Cosmi, C, Mura, R, Battisti, L, Maso, LD, Mosso, ML, Cappello, TD, Vercellino, PC, Orengo, MA, Celesia, MV, Cercato, MC, Artioli, ME, Vitale, MF, Rosa, MG, Giurdanella, MC, Rollo, PC, Ruggeri, MG, Romagna, Rt, Contrino, ML, Ziino, AC, Fanetti, AC, Annulli, ML, Gonzalez, ME, Gentilini, MA, Rosa, FL, Petrinelli, AM, Grazia, Ld, Cin, AD, Fiore, AR, Limina, RM, Sardo, AS, Lavecchia, AM, Cascio, MA, Brucculeri, MA, Adamo, MS, Sini, GM, de Leon, MP, Goldoni, CA, VALSECCHI, MARIA GRAZIA, BIONDI, ANDREA, Roncarolo, MG, Abate, ME, Mura, RM, Battisti, L., Pisani, P, Buzzoni, C, Crocetti, E, Maso, L, Rondelli, R, Alessi, D, Aricò, M, Bidoli, E, Ferrari, A, Fusco, M, Gatta, G, Guzzinati, S, Jankovic, M, Locatelli, F, Maule, M, Mosso, M, Pastore, G, Pession, A, Rashid, I, Sacerdote, C, Terracini, B, Tognazzo, S, Trama, A, Ferretti, S, Porta, F, Mazzoleni, G, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Cappello, T, Giacomin, A, Vercellino, P, Andreone, S, Marzola, L, Migliari, E, Carletti, N, Nenci, I, Caldarella, A, Corbinelli, A, Intrieri, T, Manneschi, G, Nemcova, L, Ocello, C, Sacchettini, C, Zappa, M, Paci, E, Serraino, D, Angelin, T, Birri, S, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Vercelli, M, Orengo, M, Casella, C, Marani, E, Puppo, A, Celesia, M, Cogno, R, Levrieri, I, Manenti, S, Garrone, E, Quaglia, A, Pannozzo, F, Busco, S, Ramazzotti, V, Cercato, M, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Valerio, O, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, Tamburrino, S, Fattoruso, S, Bisanti, L, Autelitano, M, Cuccaro, F, Randi, G, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Federico, M, Artioli, M, Valla, K, Braghiroli, B, Cirilli, C, Luminari, S, Pirani, M, Ferrari, L, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, M, Michiara, M, Bozzani, F, Sgargi, P, Tumino, R, Rosa, M, Cascone, G, Frasca, G, Giurdanella, M, Martorana, C, Morana, G, Nicita, C, Rollo, P, Ruggeri, M, Sigona, A, Spata, E, Vacirca, S, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Pellegri, C, Vicentini, M, D'Angelo, S, Balottari, P, Romagna, R, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Tonelli, C, Amadori, M, Cremone, L, Iannelli, A, Senatore, G, Zevola, A, Sechi, O, Budroni, M, Cesaraccio, R, Pirino, D, Carboni, D, Fiori, G, Soddu, M, Mameli, G, Mura, F, Contrino, M, Madeddu, A, Tisano, F, Sciacca, S, Muni, A, Mizzi, M, Russo, M, Sacco, G, Aletta, P, Ziino, A, Tessandori, R, Fanetti, A, Maspero, S, Cecconami, L, Annulli, M, Moroni, E, Gonzalez, M, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Piffer, S, Rizzello, R, Gentilini, M, Cappelletti, M, Rosa, F, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, A, Solimene, C, Bianconi, F, Brunori, V, Crosignani, P, Tagliabue, G, Contiero, P, Preto, L, Tittarelli, A, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, Costa, E, Grazia, L, Zambon, P, Baracco, M, Bovo, E, Cin, A, Fiore, A, Greco, A, Monetti, D, Rosano, A, Stocco, C, Donato, F, Limina, R, Adorni, A, Andreis, P, Zani, G, Piovani, F, Salvi, O, Puleio, M, Vitarelli, S, Candela, G, Pappalardo, G, Scuderi, T, Lottero, B, Ribaudo, M, Ricci, P, Guarda, L, Gatti, L, Bozzeda, A, Dall'Acqua, M, Pironi, V, Sardo, A, Mazzei, A, Sirianni, N, Lavecchia, A, Mancuso, P, Vitale, F, Cusimano, R, Amodio, R, Guttadauro, A, Ravazzolo, B, Bucalo, G, Trapani, C, Sunseri, R, Cascio, M, Brucculeri, M, Adamo, M, Mannino, R, Mistretta, A, Costa, A, Rudisi, G, Gola, G, Corti, M, Prosperini, E, Grandi, L, Sciacchitano, S, Fidelbo, M, Benedetto, G, Vasquez, E, Torrisi, A, Pesce, P, Calabretta, L, Bella, F, Leone, A, Ieni, A, Varvarà, M, Castaing, M, Di Prima, A, Benedetto, A, Paderni, F, Usala, M, Pala, F, Sini, G, Pintori, N, Canu, L, Demurtas, G, Doa, N, Lazzarato, F, Magnani, C, Merletti, F, Sarcerdote, C, Macerata, V, de Leon, M, Domati, F, Rossi, G, Goldoni, C, Rossi, F, De Gaetani, C, Benatti, P, Roncucci, L, Di Gregorio, C, Pedroni, M, Pezzi, A, Maffei, S, Mariani, F, Borsi, E, Cocchioni, M, Pascucci, C, Gennaro, V, Lazzarotto, A, Benfatto, L, Mazzucco, G, Montanaro, F, Traina, A, Carruba, G, Dolcemascolo, C, Staiti, R, Zarcone, M, Bisogno, G, Cuttini, M, De Rosa, M, Haupt, R, Soresina, A, Valsecchi, M, Fagioli, F, Bona, G, Dini, G, Conter, V, Biondi, A, Zecca, M, Fedeli, F, Massimino, M, Nespoli, L, Roncarolo, M, Basso, G, Cesaro, S, Memo, L, Bellettato, M, Tamaro, P, Mascarin, M, Rosolen, A, Izzi, G, Paolucci, P, Borgna Pignatti, C, Vecchi, V, Abate, M, D'Ambrosio, A, Favre, C, Caniglia, M, Pierani, P, Felici, L, Visani, G, Fioritoni, G, Foà, R, Riccardi, R, Frega, G, Clerico, A, Casale, F, Poggi, V, Amendola, G, Filosa, A, Ladogana, S, Presta, G, Tornesello, A, De Mattia, D, Consarino, C, Nobile, F, Sperlì, D, D'Angelo, P, Marino, S, Cosmi, C, Mura, R, Battisti, L, Maso, LD, Mosso, ML, Cappello, TD, Vercellino, PC, Orengo, MA, Celesia, MV, Cercato, MC, Artioli, ME, Vitale, MF, Rosa, MG, Giurdanella, MC, Rollo, PC, Ruggeri, MG, Romagna, Rt, Contrino, ML, Ziino, AC, Fanetti, AC, Annulli, ML, Gonzalez, ME, Gentilini, MA, Rosa, FL, Petrinelli, AM, Grazia, Ld, Cin, AD, Fiore, AR, Limina, RM, Sardo, AS, Lavecchia, AM, Cascio, MA, Brucculeri, MA, Adamo, MS, Sini, GM, de Leon, MP, Goldoni, CA, VALSECCHI, MARIA GRAZIA, BIONDI, ANDREA, Roncarolo, MG, Abate, ME, Mura, RM, and Battisti, L.
Abstract: This study describes up-to-date cancer incidence and survival in Italian paediatric and adolescent patients, based on data collected by the network of Italian cancer registries (AIRTUM). It updates the monograph published on the same topic in 2008. The main objective of this monograph is to present the statistics according to standard rigorous epidemiological methods and disseminate them to a wide range of readers, including the lay public. Given the deep impact of the 2008 monograph on the general public, in this update we complement descriptive statistics with additional data and commentaries on issues of importance for public health, in order to provide unambiguous criteria on how to interpret the statistics. The study is the result of the collaboration between AIRTUM and AIEOP (Italian Association of Paediatric Haematology and Oncology) with contributions from interested parties, including representatives of parent associations. The monograph is divided into three parts. The first part presents incidence rates, survival probabilities, and time trends, by sex, age, geographical area, and cancer site or type, by means of tables and graphs as in the previous monograph, to facilitate direct comparisons. Four articles summarize and comment the results. The second part uses data from AIRTUM and AIEOP to outline patient management and health care issues; it includes estimates of the number of new cases in the next decade and of young adults living after a paediatric cancer diagnosis. Health organizational aspects of treatment services for paediatric patients, based on the AIEOP database, are also discussed, along with long-term complications in cured patients. The third section describes the changes in mortality trends due to improving therapies and healthcare services, and discusses risk factors and prevention of childhood cancer, late adverse events in cured patients, and other related issues.
Published: 2013

8. R40 - Evaluation of diagnostic investigations used in breast cancer patients resident in Latina province during three years follow up after diagnosis

Author: Busco, S., Sperduti, I., Pistillucci, G., Cirino, C., Salesi, N., Sciacca, V., Di Cocco, B., Ciorra, A., Di Palma, T., Rossi, R., Calabretta, F., Cardillo, F., Fattoruso, S., Fiori, M., Burchi, D., Pannozzo, F., Albertoni, F., and Veltri, E.
Published: 2015
Full Text: View/download PDF

9. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines

Author: Di Lauro, L., primary, Fattoruso, S. I., additional, Giacinti, L., additional, Vici, P., additional, Sergi, D., additional, and Lopez, M., additional
Published: 2009
Full Text: View/download PDF

10. Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study

Author: Di Lauro, L., primary, Giacinti, L., additional, Arena, M. G., additional, Fattoruso, S. I., additional, Foggi, P., additional, and Lopez, M., additional
Published: 2008
Full Text: View/download PDF

11. Italian cancer figures, report 2012: Cancer in children and adolescents

Author: Pisani, P, Buzzoni, C, Crocetti, E, Maso, Ld, Rondelli, R, Alessi, D, Aricò, M, Bidoli, E, Ferrari, A, Fusco, M, Gatta, G, Guzzinati, S, Jankovic, M, Locatelli, F, Maule, M, Mosso, Ml, Pastore, G, Pession, A, Rashid, I, Sacerdote, C, Terracini, B, Tognazzo, S, Trama, A, Ferretti, S, Porta, F, Mazzoleni, G, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Cappello, Td, Giacomin, A, Vercellino, Pc, Andreone, S, Marzola, L, Migliari, E, Carletti, N, Nenci, I, Caldarella, A, Corbinelli, A, Intrieri, T, Manneschi, G, Nemcova, L, Ocello, C, Sacchettini, C, Zappa, M, Paci, E, Serraino, D, Angelin, T, Birri, S, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Vercelli, M, Orengo, Ma, Casella, C, Marani, E, Puppo, A, Celesia, Mv, Cogno, R, Levrieri, I, Manenti, S, Garrone, E, Quaglia, A, Pannozzo, F, Busco, S, Ramazzotti, V, Cercato, Mc, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Valerio, O, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, Tamburrino, S, Fattoruso, S, Bisanti, L, Autelitano, M, Cuccaro, F, Randi, G, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Federico, M, Artioli, Me, Valla, K, Braghiroli, B, Cirilli, C, Luminari, S, Pirani, M, Ferrari, L, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, Mf, Michiara, M, Bozzani, F, Sgargi, P, Tumino, R, Rosa, Mg, Cascone, G, Frasca, G, Giurdanella, Mc, Martorana, C, Morana, G, Nicita, C, Rollo, Pc, Ruggeri, Mg, Sigona, A, Spata, E, Vacirca, S, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Pellegri, C, Vicentini, M, D'Angelo, S, Balottari, P, Romagna, Rt, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Tonelli, C, Amadori, M, Cremone, L, Iannelli, A, Senatore, G, Zevola, A, Sechi, O, Budroni, M, Cesaraccio, R, Pirino, D, Carboni, D, Fiori, G, Soddu, M, Mameli, G, Mura, F, Contrino, Ml, Madeddu, A, Tisano, F, Sciacca, S, Muni, A, Mizzi, M, Russo, M, Sacco, G, Aletta, P, Ziino, Ac, Tessandori, R, Fanetti, Ac, Maspero, S, Cecconami, L, Annulli, Ml, Moroni, E, Gonzalez, Me, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Piffer, S, Rizzello, R, Gentilini, Ma, Cappelletti, M, Rosa, Fl, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, Am, Solimene, C, Bianconi, F, Brunori, V, Crosignani, P, Tagliabue, G, Contiero, P, Preto, L, Tittarelli, A, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, Costa, E, Grazia, Ld, Zambon, P, Baracco, M, Bovo, E, Cin, Ad, Fiore, Ar, Greco, A, Monetti, D, Rosano, A, Stocco, C, Donato, F, Limina, Rm, Adorni, A, Andreis, P, Zani, G, Piovani, F, Salvi, O, Puleio, M, Vitarelli, S, Candela, G, Pappalardo, G, Scuderi, T, Lottero, B, Ribaudo, M, Ricci, P, Guarda, L, Gatti, L, Bozzeda, A, Dall'Acqua, M, Pironi, V, Sardo, As, Mazzei, A, Sirianni, N, Lavecchia, Am, Mancuso, P, Vitale, F, Cusimano, R, Amodio, R, Guttadauro, A, Ravazzolo, B, Bucalo, G, Trapani, C, Sunseri, R, Cascio, Ma, Brucculeri, Ma, Adamo, Ms, Mannino, R, Mistretta, A, Costa, A, Rudisi, G, Gola, G, Corti, M, Prosperini, E, Grandi, L, Sciacchitano, S, Fidelbo, M, Benedetto, G, Vasquez, E, Torrisi, A, Pesce, P, Calabretta, L, Bella, F, Leone, A, Ieni, A, Varvarà, M, Castaing, M, Di Prima, A, Benedetto, A, Paderni, F, Usala, M, Pala, F, Sini, Gm, Pintori, N, Canu, L, Demurtas, G, Doa, N, Lazzarato, F, Magnani, C, Merletti, F, Sarcerdote, C, Macerata, V, de Leon MP, Domati, F, Rossi, G, Goldoni, Ca, Rossi, F, De Gaetani, C, Benatti, P, Roncucci, L, Di Gregorio, C, Pedroni, M, Pezzi, A, Maffei, S, Mariani, F, Borsi, E, Cocchioni, M, Pascucci, C, Gennaro, V, Lazzarotto, A, Benfatto, L, Mazzucco, G, Montanaro, F, Traina, A, Carruba, G, Dolcemascolo, C, Staiti, R, Zarcone, M, Bisogno, G, Cuttini, M, De Rosa, M, Haupt, R, Soresina, A, Valsecchi, Mg, Fagioli, F, Bona, G, Dini, G, Conter, V, Biondi, A, Zecca, M, Fedeli, F, Massimino, M, Nespoli, L, Roncarolo, Mg, Basso, G, Cesaro, S, Memo, L, Bellettato, M, Tamaro, Paolo, Mascarin, M, Rosolen, A, Izzi, G, Paolucci, P, Borgna Pignatti, C, Vecchi, V, Abate, Me, D'Ambrosio, A, Favre, C, Caniglia, M, Pierani, P, Felici, L, Visani, G, Fioritoni, G, Foà, R, Riccardi, R, Frega, G, Clerico, A, Casale, F, Poggi, V, Amendola, G, Filosa, A, Ladogana, S, Presta, G, Tornesello, A, De Mattia, D, Consarino, C, Nobile, F, Sperlì, D, D'Angelo, P, Marino, S, Cosmi, C, Mura, Rm, Battisti, L., Pisani, P, Buzzoni, C, Crocetti, E, Maso, Ld, Rondelli, R, Alessi, D, Aricò, M, Bidoli, E, Ferrari, A, Fusco, M, Gatta, G, Guzzinati, S, Jankovic, M, Locatelli, F, Maule, M, Mosso, Ml, Pastore, G, Pession, A, Rashid, I, Sacerdote, C, Terracini, B, Tognazzo, S, Trama, A, Ferretti, S, Porta, F, Mazzoleni, G, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Cappello, Td, Giacomin, A, Vercellino, Pc, Andreone, S, Marzola, L, Migliari, E, Carletti, N, Nenci, I, Caldarella, A, Corbinelli, A, Intrieri, T, Manneschi, G, Nemcova, L, Ocello, C, Sacchettini, C, Zappa, M, Paci, E, Serraino, D, Angelin, T, Birri, S, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Vercelli, M, Orengo, Ma, Casella, C, Marani, E, Puppo, A, Celesia, Mv, Cogno, R, Levrieri, I, Manenti, S, Garrone, E, Quaglia, A, Pannozzo, F, Busco, S, Ramazzotti, V, Cercato, Mc, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Valerio, O, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, Tamburrino, S, Fattoruso, S, Bisanti, L, Autelitano, M, Cuccaro, F, Randi, G, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Federico, M, Artioli, Me, Valla, K, Braghiroli, B, Cirilli, C, Luminari, S, Pirani, M, Ferrari, L, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, Mf, Michiara, M, Bozzani, F, Sgargi, P, Tumino, R, Rosa, Mg, Cascone, G, Frasca, G, Giurdanella, Mc, Martorana, C, Morana, G, Nicita, C, Rollo, Pc, Ruggeri, Mg, Sigona, A, Spata, E, Vacirca, S, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Pellegri, C, Vicentini, M, D'Angelo, S, Balottari, P, Romagna, Rt, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Tonelli, C, Amadori, M, Cremone, L, Iannelli, A, Senatore, G, Zevola, A, Sechi, O, Budroni, M, Cesaraccio, R, Pirino, D, Carboni, D, Fiori, G, Soddu, M, Mameli, G, Mura, F, Contrino, Ml, Madeddu, A, Tisano, F, Sciacca, S, Muni, A, Mizzi, M, Russo, M, Sacco, G, Aletta, P, Ziino, Ac, Tessandori, R, Fanetti, Ac, Maspero, S, Cecconami, L, Annulli, Ml, Moroni, E, Gonzalez, Me, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Piffer, S, Rizzello, R, Gentilini, Ma, Cappelletti, M, Rosa, Fl, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, Am, Solimene, C, Bianconi, F, Brunori, V, Crosignani, P, Tagliabue, G, Contiero, P, Preto, L, Tittarelli, A, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, Costa, E, Grazia, Ld, Zambon, P, Baracco, M, Bovo, E, Cin, Ad, Fiore, Ar, Greco, A, Monetti, D, Rosano, A, Stocco, C, Donato, F, Limina, Rm, Adorni, A, Andreis, P, Zani, G, Piovani, F, Salvi, O, Puleio, M, Vitarelli, S, Candela, G, Pappalardo, G, Scuderi, T, Lottero, B, Ribaudo, M, Ricci, P, Guarda, L, Gatti, L, Bozzeda, A, Dall'Acqua, M, Pironi, V, Sardo, A, Mazzei, A, Sirianni, N, Lavecchia, Am, Mancuso, P, Vitale, F, Cusimano, R, Amodio, R, Guttadauro, A, Ravazzolo, B, Bucalo, G, Trapani, C, Sunseri, R, Cascio, Ma, Brucculeri, Ma, Adamo, M, Mannino, R, Mistretta, A, Costa, A, Rudisi, G, Gola, G, Corti, M, Prosperini, E, Grandi, L, Sciacchitano, S, Fidelbo, M, Benedetto, G, Vasquez, E, Torrisi, A, Pesce, P, Calabretta, L, Bella, F, Leone, A, Ieni, A, Varvarà, M, Castaing, M, Di Prima, A, Benedetto, A, Paderni, F, Usala, M, Pala, F, Sini, Gm, Pintori, N, Canu, L, Demurtas, G, Doa, N, Lazzarato, F, Magnani, C, Merletti, F, Sarcerdote, C, Macerata, V, de Leon, Mp, Domati, F, Rossi, G, Goldoni, Ca, Rossi, F, De Gaetani, C, Benatti, P, Roncucci, L, Di Gregorio, C, Pedroni, M, Pezzi, A, Maffei, S, Mariani, F, Borsi, E, Cocchioni, M, Pascucci, C, Gennaro, V, Lazzarotto, A, Benfatto, L, Mazzucco, G, Montanaro, F, Traina, A, Carruba, G, Dolcemascolo, C, Staiti, R, Zarcone, M, Bisogno, G, Cuttini, M, De Rosa, M, Haupt, R, Soresina, A, Valsecchi, Mg, Fagioli, F, Bona, G, Dini, G, Conter, V, Biondi, A, Zecca, M, Fedeli, F, Massimino, M, Nespoli, L, Roncarolo, Mg, Basso, G, Cesaro, S, Memo, L, Bellettato, M, Tamaro, Paolo, Mascarin, M, Rosolen, A, Izzi, G, Paolucci, P, Borgna Pignatti, C, Vecchi, V, Abate, Me, D'Ambrosio, A, Favre, C, Caniglia, M, Pierani, P, Felici, L, Visani, G, Fioritoni, G, Foà, R, Riccardi, R, Frega, G, Clerico, A, Casale, F, Poggi, V, Amendola, G, Filosa, A, Ladogana, S, Presta, G, Tornesello, A, De Mattia, D, Consarino, C, Nobile, F, Sperlì, D, D'Angelo, P, Marino, S, Cosmi, C, Mura, Rm, Battisti, L., Maso, L, Mosso, M, Cappello, T, Vercellino, P, Orengo, M, Celesia, M, Cercato, M, Artioli, M, Vitale, M, Rosa, M, Giurdanella, M, Rollo, P, Ruggeri, M, Romagna, R, Contrino, M, Ziino, A, Fanetti, A, Annulli, M, Gonzalez, M, Gentilini, M, Rosa, F, Petrinelli, A, Grazia, L, Cin, A, Fiore, A, Limina, R, Lavecchia, A, Cascio, M, Brucculeri, M, Sini, G, de Leon, M, Goldoni, C, Valsecchi, M, Roncarolo, M, Tamaro, P, Abate, M, Mura, R, Battisti, L, AIRTUM Working Group[.., Enrica Borsi, ], CCM, and AIEOP Working Group
Subjects: Male, Parents, cancer incidence, Adolescent, Epidemiology, Aftercare, cancer in adolescents, Young Adult, children, Neoplasms, cancer in children, Italian population, cancer, Cluster Analysis, Humans, Registries, Survivors, Age of Onset, Mortality, Child, cancer survival, Incidence, Environmental and Occupational Health, Infant, Newborn, Disease Management, Infant, pediatric, Survival Rate, Italy, Child, Preschool, Public Health, Environmental and Occupational Health, Female, Public Health, Morbidity, Forecasting
Abstract: OBJECTIVES: This study describes up-to-date cancer incidence and survival in Italian paediatric and adolescent patients, based on data collected by the network of Italian cancer registries (AIRTUM). It updates the monograph published on the same topic in 2008. The main objective of this monograph is to present the statistics according to standard rigorous epidemiological methods and disseminate them to a wide range of readers, including the lay public. Given the deep impact of the 2008 monograph on the general public, in this update we complement descriptive statistics with additional data and commentaries on issues of importance for public health, in order to provide unambiguous criteria on how to interpret the statistics. The study is the result of the collaboration between AIRTUM and AIEOP (Italian Association of Paediatric Haematology and Oncology) with contributions from interested parties, including representatives of parent associations. The monograph is divided into three parts. The first part presents incidence rates, survival probabilities, and time trends, by sex, age, geographical area, and cancer site or type, by means of tables and graphs as in the previous monograph, to facilitate direct comparisons. Four articles summarize and comment the results. The second part uses data from AIRTUM and AIEOP to outline patient management and health care issues; it includes estimates of the number of new cases in the next decade and of young adults living after a paediatric cancer diagnosis. Health organizational aspects of treatment services for paediatric patients, based on the AIEOP database, are also discussed, along with long-term complications in cured patients. The third section describes the changes in mortality trends due to improving therapies and healthcare services, and discusses risk factors and prevention of childhood cancer, late adverse events in cured patients, and other related issues. MATERIAL AND METHODS: Data herein presented were provided by AIRTUM population-based cancer registries, covering 47%of the Italian population below age 20 years, in the period 2003-2008. Quality of cancer registration in Italy is elevated, with high proportions of microscopically verified diagnoses (91%in the 0-14 years age group and 96% between 15 and 19 years of age) and a very small proportion of cases collected through death certificate only (0.1%).The proportion of cases in diagnostic groups XI (other malignant epithelial neoplasms) and XII (other and unspecified neoplasms) of the International Classification for Childhood Cancer (ICCC), based on the third revision of the International Classification of Diseases for Oncology (ICD-O-3), were 7.0% in the 0-14 years age group and 26.0%in the 15-19 years age group.The ratio between mortality and incidence was 17.7% in both children and adolescents. Detailed results are presented in 24 fact sheets for the 12 major ICCC-3 diagnostic groups and 10 sub-groups of special interest; the series is completed by a sheet on all malignant tumours and one on all tumours including non-malignant neoplasms of the central nervous system. All sheets include results for three age groups (0-14, 15-19, and 0-19 years) and are followed by two commentaries on incidence in the recent period, one on trends and the other on survival. Incidence rates were age-standardized on the European population and presented per million children. Incidence rates are also presented by age group, sex, and geographical area. Incidence trends were evaluated for two periods, 1988-2008 and 1998-2008, using estimated annual percent changes, and survival estimates were calculated by age and period. Indicators and corresponding 95% confidence intervals are shown in forms of graphics and tables at the end of the monograph and online at http://www.registri-tumori.it. Geographical analyses were conducted rearranging cancer registries into four macroareas (North-West, North-East, Centre, and South and Islands). Age groups were the same used in descriptive studies on children worldwide (0, 1-4, 5-9, 10- 14 years for paediatric tumours and 15-19 years for adolescents). Incidence trend analyses included cancer registries with three or more years of registration in the 5-year period, using Poisson regression models. Observed survival was computed according to the Kaplan-Meier method. The estimate of expected cases in the next decade was based on observed incidence rates in the most recent period, extended to the Italian estimated population of children and adolescents in the periods 2011-2015 and 2016-2020. The AIEOP database (Modello 1.01) allowed us to compare the number of patients treated and followed-up in specialized centres with expected cases based on AIRTUM estimates. The AIEOP database also provided information regarding health care migration throughout Italian regions and the number of foreign (immigrated) children treated in Italian AIEOP centres. RESULTS: In the period 2003-2008, 31 cancer registries reported 4,473 incident malignant neoplasms, 2,855 in children and 1,618 in adolescents. Cancer incidence rates were 164 cases per million in children aged 14 years or below and 269 cases per million in patients aged 15-19 years. Limited geographical variations emerged. In children (0-14 years) a significant increase in malignant cancer incidence was observed until 1997 (APC: +3.2%), followed by a plateau (APC: -1.1%not statistically significant).Until the late Nineties, a statistically significant increase was also observed in the incidence of all leukaemias in males (APC: +5.7%), lymphoid leukaemias (APC: +5.6%), representing 80% of all leukaemias, Hodgkin and non- Hodgkin lymphomas (APC: +6.3%). A significant decrease emerged for lymphoid leukaemia starting in 1995 (APC: -1.9%), while no substantial change in cancer incidence rates was observed in the last decade of observation for all malignant neoplasms and lymphomas. In addition, no variation emerged for malignant (according to the most recent classification) central nervous system (CNS) neoplasms, while an annual increase of 1.8% (significant) was observed in the period 1988-2008, when non-malignant tumours were included. Increases in cancer incidence were observed throughout the study period for neuroblastoma (APC: +1.9%) and epithelial tumours or melanoma (APC: +4.1%). In the period 1998-2008, in addition to lymphoid leukaemias, a significant decrease was observed for all malignant neoplasms, lymphomas in girls, CNS tumours (males and females), and renal tumours in girls, while no increases were observed in this age group. In adolescents (15-19 years) between 1988 and 2008, a significant increase in incidence rates was observed (APC: +2.0%) for all malignant neoplasms, all lymphomas (APC: +2.9%; in particular Hodgkin lymphoma, APC: +3.6%), thyroid cancer (APC: +6.1%), and melanoma (APC: +8.1%). Conversely, lymphoid leukaemia is the only neoplasm showing a long-term decrease in adolescents. Recent trends (1998-2008) confirm the long-term increases only for all malignant neoplasms in girls and thyroid cancer (APC: +7.9%, boys and girls), while a decrease in bone tumour incidence emerged in girls, albeit based only on 46 cases. Cancer mortality in children showed a persistent decrease for all neoplasms and even for more frequent cancer sites or types, and mortality rates for cancer were three-fold higher in the early Seventies than in 2008. In addition, five-year survival after cancer diagnosis increased in the last three decades and was still increasing in the period 2003- 2008, reaching 82% in children and 86% in adolescents. In the period 2008-2010, 4,488 children (0-14 years) were treated in one of the AIEOP clinical centres and we estimate, based on the above-presented incidence rates, that they represented 92% of all cancer cases in Italy. However, in adolescents, the proportion of patients treated in AIEOP centres was only 25%. A migration of patients living in the South of Italy to Central and Northern Italy emerged from AIEOP information. The expected number of cancer cases in children aged between 0 and 14 years of age is approximately 7,000 in the period 2016- 2020, while the corresponding figure for adolescents between 15 and 19 years of age is 4,000, with no relevant variation in comparison with the previous five-year period. COMMENTS: The present findings update descriptive cancer epidemiology in children and adolescents in Italy based on data provided by an extensive network of general and specialized population-based cancer registries. Data obtained from cancer registries are supplemented by additional information collected by specialized clinical AIEOP centres and mortality reports collected by the National Institute of Statistics (ISTAT). Incidence rates reported in Italy were slightly higher in comparison to other developed Countries, but relatively consistent between different Italian areas. Our results also showed that the significant increase in cancer incidence observed until the end of Nineties has halted, with the exception solely of thyroid cancer in adolescents. Efficacy of therapeutic protocols has improved constantly since the Seventies, and recent findings confirm this trend in all age groups and, in particular, for rarer tumours and cancer types that have very poor prognosis. Findings derived from cross-analysis with AIEOP data suggest that it is possible to further improve the efficiency of our healthcare system, in particular for adolescents; migration can be reduced with a more rational use of hospitals throughout Italy.

12. Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

Author: Zorzi, M., Lucia Mangone, Anghinoni, E., Baracco, S., Borciani, E., Caldarella, A., Falcini, F., Fanetti, A. C., Ferretti, S., Rossi, P. G., Michiara, M., Randi, G., Stracci, F., Vicentini, M., Zucchetto, A., Zappa, M., Giacomin, A., Azzoni, A., Baldazzi, P., Collina, N., Pandolfi, P., Biavati, P., Gualandi, G., Sciacca, S., Pesce, P., Torrisi, A., Sciacchitano, C., Fidelbo, M., Finarelli, A. C., Naldoni, C., Bianchi, P. S., Landi, P., Matarese, V., Togni, A., Palmonari, C., Crocetti, E., Grazzini, G., Manneschi, G., Mantellini, P., Serraino, D., Bidoli, E., Taborelli, M., Gini, A., Virdone, S., Puppo, A., Casella, C., Celesia, M., Cogno, R., Marani, E., Bugliarello, E., Fattoruso, S., Tamburo, L., Tamburrino, S., Bellardini, P., Autelitano, M., Frammartino, B., Bisanti, L., Ghilardi, S., Leone, R., Corradini, R., Girolamo, F., Valla, K., Palombino, R., Gigli, L., Spena, S. R., Vitale, M. F., Cascio, M. A., Mannino, R., Mazzucco, W., Mistretta, A., Ravazzolo, B., Sgarzi, P., Bozzani, F., Zatelli, M., Zurlini, C., Caruana, P., Seghini, P., Gatti, G., Prazzoli, R., Campari, C., Paterlini, L., Cassetti, T., Sassatelli, R., Imolesi, C., Casale, C., Serafini, M., Vattiato, R., Giuliani, O., Cesaraccio, R., Sechi, O., Budroni, M., Madeddu, A., Contrino, M. L., Ziino, A. C., Russo, M., Tisano, F., Maspero, S., Moroni, E., Cometti, I., Gentilini, M., Piffer, S., Pretis, G., Caciagli, P., Pertile, R., Bianconi, F., Bucchi, D., Galeotti, M. E., Malaspina, M., Greco, A., Fiore, A. R., Stocco, C. F., Fedato, C., Zorzi, M., Mangone, L., Anghinoni, E., Baracco, S., Borciani, E., Caldarella, A., Falcini, F., Fanetti, A., Ferretti, S., Rossi, P., Michiara, M., Randi, G., Stracci, F., Vicentini, M., Zucchetto, A., Zappa, M., Giacomin, A., Azzoni, A., Baldazzi, P., Collina, N., Pandolfi, P., Biavati, P., Gualandi, G., Sciacca, S., Pesce, P., Torrisi, A., Sciacchitano, C., Fidelbo, M., Finarelli, A., Naldoni, C., De'Bianchi, P., Landi, P., Matarese, V., De Togni, A., Palmonari, C., Crocetti, E., Grazzini, G., Manneschi, G., Mantellini, P., Serraino, D., Bidoli, E., Taborelli, M., Gini, A., Virdone, S., Puppo, A., Casella, C., Celesia, M., Cogno, R., Marani, E., Bugliarello, E., Fattoruso, S., Tamburo, L., Tamburrino, S., Bellardini, P., Autelitano, M., Frammartino, B., Bisanti, L., Ghilardi, S., Leone, R., Corradini, R., De Girolamo, F., Valla, K., Palombino, R., Gigli, L., Spena, S., Vitale, M., Cascio, M., Mannino, R., Mazzucco, W., Mistretta, A., Ravazzolo, B., Sgarzi, P., Bozzani, F., Zatelli, M., Zurlini, C., Caruana, P., Seghini, P., Gatti, G., Prazzoli, R., Campari, C., Paterlini, L., Cassetti, T., Sassatelli, R., Imolesi, C., Casale, C., Serafini, M., Vattiato, R., Giuliani, O., Cesaraccio, R., Sechi, O., Budroni, M., Madeddu, A., Contrino, M., Ziino, A., Russo, M., Tisano, F., Maspero, S., Moroni, E., Cometti, I., Gentilini, M., Piffer, S., De Pretis, G., Caciagli, P., Pertile, R., Bianconi, F., Bucchi, D., Galeotti, M., Malaspina, M., Greco, A., Fiore, A., Stocco, C., and Fedato, C.
Subjects: Colorectal cancer, Colorectal cancer screening, Italy, Epidemiology, Public Health, Environmental and Occupational Health, Settore MED/42 - Igiene Generale E Applicata
Abstract: The impact of organized screening programmes on colorectal cancer (CRC) can be observed at a population level only several years after the implementation of screening. We compared CRC characteristics by diagnostic modality (screen-detected, non-screen-detected) as an early outcome to monitor screening programme effectiveness. Data on CRCs diagnosed in Italy from 2000 to 2008 were collected by several cancer registries. Linkage with screening datasets made it possible to divide the cases by geographic area, implementation of screening, and modality of diagnosis (screen-detected, non-screen-detected).We compared the main characteristics of the different subgroups of CRCs through multivariate logistic regression models. The study included 23,668 CRCs diagnosed in subjects aged 50-69 years, of which 11.9%were screendetected (N=2,806), all from the North-Centre of Italy. Among screen-detected CRCs, we observed a higher proportion of males, of cases in the distal colon, and a higher mean age of the patients. Compared with pre-screening cases, screen-detected CRCs showed a better distribution by stage at diagnosis (OR for stage III or IV: 0.40, 95%CI: 0.36-0.44) and grading (OR for poorly differentiated CRCs was 0.86, 95%CI: 0.75-1.00). Screen-detected CRCs have more favourable prognostic characteristics than non-screen-detected cases. A renewed effort to implement screening programmes throughout the entire country is recommended.

13. Fiberoptic bronchoscopy as diagnostic tool in primitive lung cancer,Ruolo diagnostico della fibrobroncoscopia nelle neoplasie polmonari primitive

Author: Filippetti, M., Visca, P., Bordignon, V., Sergi, D., Marolla, P., Gianluigi FERRETTI, Tonachella, R., Corzani, F., Fattoruso, S. I., and Di Lauro, L.

14. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment

Author: Vici, P., Viola, G., Rossi, S., Botti, C., Vitucci, C., Domenico Sergi, Ferranti, F. R., Saracca, E., Di Lauro, L., Corsetti, S., Foggi, P., Fattoruso, S. I. S., and Lopez, M.

15. Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer,Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo

Author: Fattoruso, S. I. S., Rossi, S., Vici, P., Di Filippo, F., Claudio Botti, Di Lauro, L., Foggi, P., Saracca, E., Ferranti, F. R., Visca, P., and Lopez, M.

16. Development of docetaxel in the adjuvant chemotherapy of breast cancer,Sviluppo del docetaxel nella chemioterapia adiuvante del cancro della mammella

Author: Fattoruso, S. I. S., Rossi, S., Di Lauro, L., Botti, C., Patrizia Vici, and Lopez, M.

17. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients

Author: Vici, P., Viola, G., Claudio Botti, Rossi, S., Vitucci, C., Corsetti, S., Di Lauro, L., Sergi, D., Foggi, P., Perri, P., Tirelli, C., Mottolese, M., Fattoruso, S. I. S., and Lopez, M.

18. Real-Time Obstacle Detection and Field Mapping System Using LIDAR-ToF Sensors for Small UAS

Author: Gennaro Ariante, Giuseppe Del Core, Umberto Papa, Salvatore Ponte, Di Francia, G., Di Natale, C., B. Alfano, S. De Vito, A. Del Giudice, E. Esposito, S. Fattoruso, S. Ferlito, F. Formisano, E. Massera, M.L. Miglietta, T. Polichetti, Ariante, Gennaro, Papa, Umberto, Ponte, Salvatore, Del Core, Giuseppe, Di Natale, C., Lorenzelli, L., Dalla Betta, G., Adami, A., Mulloni, V. (Eds.), and Mulloni, V.
Subjects: Lidar, Detect and avoid, Computer science, Arduino, Obstacle, Real-time computing, UAS, UAV, DAA, Lidar, Sensor Fusion, ToF, Kalman Filter, ComputerApplications_COMPUTERSINOTHERSYSTEMS, Ranging, Kalman filter, Sensor fusion, Search and rescue
Abstract: UASs (Unmanned Aircraft Systems) are becoming increasingly popular in the last years, for both military and civil applications. They are widely used in var-ious tasks, such as search and rescue, disaster assessment, urban traffic moni-toring, 3D mapping, etc., that would be risky or impossible to perform for a human. DAA (Detect and Avoid) is a new UAS technology necessary to safely avoid obstacles or other UASs and aircrafts. In this work low-cost sensors, namely, a DAA architecture based on a LIDAR (Light Detection and Ranging), and a ToF (Time of Flight) sensor, are installed on a small unmanned rotorcraft to estimate its distance from an obstacle and for field mapping. To correct the data from systematic errors (bias) and measurement noise, Kalman filtering and a criterion of optimal estimation have been implemented. Collected data are sent to a microcontroller (Arduino Mega 2560), which allows for low-cost hardware implementations of multiple sensors for use in aerospace applications.
Published: 2021
Full Text: View/download PDF

19. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.

Author: Fasano M, Pirozzi M, Famiglietti V, Facchini S, Caterino M, Caroprese M, Barillaro A, Di Giovanni I, Auriemma A, Ileana Sara Fattoruso S, Somma T, Solari D, Bocchetti M, Conson M, Pacelli R, Ciardiello F, and Addeo R
Abstract: Glioblastoma multiforme is one of the most frequent and aggressive primary tumors in the central nervous system, representing >60% of all brain tumors in adults. Despite treatment, prognosis remains poor with most if not all patients experiencing disease recurrence and a 2-year survival rate of 27%. At present, no confirmed standard treatment exists for recurrent glioblastoma. Regorafenib is one of the few options available, based on results from the REGOMA trial. In the present study, a real-life retrospective investigation on the role of regorafenib in patients with recurrent glioblastoma (>60 years old) from two main Oncological Units in South Italy (Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy and Ospedale Civile San Giovanni di Dio, Frattamaggiore, Naples, Italy), was performed. The primary endpoint was overall survival (OS), whereas progression-free survival (PFS), objective response rate and disease control were secondary endpoints. Survival was then analyzed according to age, isocitrate dehydrogenase (IDH) and methylated methylguanine-DNA-methyltransferase (MGMT) status. A total of 56 patients met the eligibility criteria. The intention to treat population median PFS (mPFS) was 4.1 months and median OS (mOS) was 6.8 months. Age did not appear to have a significant influence on mPFS. mOS in MGMT-methylated patients was improved compared with that of the unmethylated group (7.7 months vs. 5.6 months). Both mOS and mPFS were longer in IDH-mutant patients. The present study was one of the first real life analyses of regorafenib in recurrent glioblastoma. The results were in line with the REGOMA trial. Age did not appear to be a prognostic factor, thus suggesting that treatment choice should not be different in elderly. MGMT methylation appeared to influence OS. To the best of our knowledge, this was the first report of regorafenib activity in older patients and, while the results were statistically significant, these should be confirmed in further studies., Competing Interests: MF: Advisory boards for MSD and Merck Serono. All other authors declare that they have no competing interests., (Copyright: © Fasano et al.)
Published: 2023
Full Text: View/download PDF

20. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.

Author: Fattoruso SIS, De Luca R, Grassadonia A, Evola S, Salvato A, Addeo R, and Cicero G
Subjects: Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cardiotoxicity drug therapy, Cardiotoxicity etiology, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Humans, Polyethylene Glycols adverse effects, Retrospective Studies, Treatment Outcome, Breast Neoplasms drug therapy, Breast Neoplasms pathology
Abstract: Background: The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment., Methods: 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1., Results: The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6-18.8) and median progression free survival was 5.8 months (95%CI:4.4-8.6). Hematologic toxicity with neutropenia was the most frequent adverse event, but the treatment was well tolerated maintained a manageable cardiotoxicity., Conclusion: Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and de-creases cardiotoxicity.
Published: 2022
Full Text: View/download PDF

21. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

Author: Maugeri-Saccà M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S, Giannarelli D, Amodio A, Boggia S, Vici P, and Di Lauro L
Subjects: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cohort Studies, Disease Progression, Docetaxel, Female, Fluorouracil administration & dosage, Humans, Leucovorin administration & dosage, Male, Middle Aged, Retrospective Studies, Stomach Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy, Taxoids therapeutic use
Abstract: Background: The role of second-line therapy in gastric cancer patients mostly stemmed from clinical trials with monochemotherapy carried out in Asian countries. Nevertheless, these results cannot be broadly generalized as molecular studies suggested the existence of different sets of deregulated gene networks correlated with ethnicity. In the present study, we investigated the activity and safety of FOLFIRI given as a second-line therapy in metastatic gastric or gastro-esophageal junction cancer patients who experienced disease progression on or after first-line docetaxel-containing chemotherapy., Methods: Patients with histologically confirmed metastatic gastric cancer who failed docetaxel-containing first-line therapy and who received FOLFIRI in second line were eligible for the study. Seventy patients treated at three Italian cancer centers between 2005 and 2012 entered the study. Patients received every 2 weeks irinotecan 180 mg/m2 as 1 h infusion on day 1, folinic acid 100 mg/m2 intravenously days 1-2, and fluorouracil as a 400 mg/m2 bolus and then 600 mg/m2 continuous infusion over 22 hours days 1-2., Results: We observed 1(1.4%) complete response, 15 (21.4%) partial response, for an overall response rate of 22.8% (95% confidence interval (CI): 13.4-32.3). Stable disease was recorded in 21 (30%) patients. Median progression-free survival and overall survival were 3.8 months (95% CI: 3.3-4.4) and 6.2 months (95% CI: 5.3-7.1), respectively. The treatment was well tolerated, as the most common G3-4 toxicities were neutropenia (28.5%) and diarrhea (14.5%)., Conclusions: FOLFIRI appears an effective and safe treatment option for pretreated metastatic gastric cancer patients, and deserves further investigation in randomized clinical trials.
Published: 2013
Full Text: View/download PDF

22. [Fiberoptic bronchoscopy as diagnostic tool in primitive lung cancer].

Author: Filippetti M, Visca P, Bordignon V, Sergi D, Marolla P, Ferretti G, Tonachella R, Corzani F, Fattoruso SI, and Di Lauro L
Subjects: Fiber Optic Technology, Humans, Sensitivity and Specificity, Bronchoscopy methods, Lung Neoplasms pathology
Abstract: Objective: The aim of this study was to assess the diagnostic role of fiberoptic bronchoscopy in primitive lung cancers in relation to the sensibility, the specificity and the cost of the examination., Materials and Methods: We analysed the diagnostic flow-charts of 473 patients with suspected primitive lung cancer consecutively examined during a period of 4 years (2003-2006). The results were analysed comparing patients observed in the period 2003-2004 with those observed during 2005-2006. The number and type of samples collected and the protocols utilized were considered., Results: In overall patients the reliability of the fiberoptic bronchoscopy was 61.7%, with a significant increase from 47.5% in 2003-2004 to 74.4% in 2005-2006. An important role in improving the diagnostic relevance of the exam was assumed by the more frequent adoption of biopsies and trans-bronchial needle aspiration on parenchyma and mediastinal lymph nodes., Conclusions: The fiberoptic-bronchoscopy associated to advanced tissue sampling techniques represents the gold standard for the diagnosis of lung cancer, due to high sensitivity and specificity and moderate cost.
Published: 2009

23. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.

Author: Vici P, Viola G, Rossi S, Botti C, Vitucci C, Sergi D, Ferranti FR, Saracca E, Di Lauro L, Corsetti S, Foggi P, Fattoruso SI, and Lopez M
Subjects: Anthracyclines administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Cross-Over Studies, Doxorubicin administration & dosage, Drug Resistance, Neoplasm, Epirubicin administration & dosage, Female, Humans, Paclitaxel administration & dosage, Prospective Studies, Randomized Controlled Trials as Topic, Taxoids administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant, Drug Administration Schedule
Abstract: Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS for the taxane-arms, but the best schedule of administration, in combination with anthracyclines or in sequence, is still a debated issue, even if the sequential strategy appears to be less toxic. Up to now, the majority of clinical trials employed the "standard" sequence, with anthracycline-based combinations fi rst, followed by taxanes. Few small phase II trials evaluated the reverse sequence, with taxanes administered fi rst, most of them in metastatic or neoadjuvant setting, suggesting efficacy and lower toxicity. An important issue to be considered is the hypothesized differences in the ability of the drugs to induce cross-resistance to each other, as suggested by data of a preclinical study, and from clinical study with a cross-over design; results of these trials suggest that the best strategy would be to administer a taxane prior to an anthracycline, also according to the Norton and Simon hypothesis. Moreover, trials evaluating the best sequence of anthracyclines and taxanes in adjuvant breast cancer setting are of small sample size, and an adequately powered randomized phase III trial is needed before definitive conclusions are reached.
Published: 2008

24. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].

Author: Fattoruso SI, Rossi S, Vici P, Di Filippo F, Botti C, Di Lauro L, Foggi P, Saracca E, Ferranti FR, Visca P, and Lopez M
Subjects: Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms genetics, Breast Neoplasms pathology, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Disease-Free Survival, Docetaxel, Doxorubicin administration & dosage, Drug Administration Schedule, Drug Resistance, Neoplasm, Epirubicin administration & dosage, Epirubicin adverse effects, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Forecasting, Genes, erbB-2, Heart Diseases chemically induced, Humans, Methotrexate administration & dosage, Methotrexate adverse effects, Paclitaxel administration & dosage, Prospective Studies, Randomized Controlled Trials as Topic, Taxoids administration & dosage, Taxoids adverse effects, Antineoplastic Agents, Phytogenic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant, Taxoids therapeutic use
Abstract: The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.
Published: 2008

25. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.

Author: Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, and Lopez M
Subjects: Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms genetics, Breast Neoplasms pathology, Carboplatin administration & dosage, Carboplatin therapeutic use, Clinical Trials, Phase III as Topic, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Disease-Free Survival, Docetaxel, Epirubicin administration & dosage, Female, Heart Diseases chemically induced, Humans, Multicenter Studies as Topic, Neoplasm Proteins antagonists & inhibitors, Paclitaxel administration & dosage, Prospective Studies, Randomized Controlled Trials as Topic, Taxoids administration & dosage, Taxoids adverse effects, Topoisomerase II Inhibitors, Trastuzumab, Antineoplastic Agents, Phytogenic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant, Genes, erbB-2, Taxoids therapeutic use
Abstract: Considering the clinical benefit of trastuzumab in advanced breast cancer, fi ve prospective adjuvant randomized trials have recently been completed and early results have been published. Two of them, (NSABP-B31 and NCCTG N9831), employed anthracycline-containing regimens with sequential paclitaxel, with or without trastuzumab. The third study, HERA trial, randomized patients after adjuvant chemotherapy into an observational arm, one or two years of trastuzumab. Results of these studies, after a median follow up of 2-3 years confirm a DFS and OS benefit for the experimental arms. The worst rate of cardiotoxicity, in terms of incidence of CHF, with the use of trastuzumab and anthracycline based regimens was 4.1% in the trastuzumab arm of the NSABP-B31 trial. Among the fi ve trastuzumab trials, two, BCIRG 006 and FinHer, employed docetaxel-based regimens. The innovative BCIRG 006 trial compared ACdocetaxel (T) with two trastuzumab-containing regimens, ACTH, and a non-anthracycline-containing regimens, TCH, with a clear advantage in DFS for both trastuzumab arms. Data from the second interim analysis indicate that, in the subgroup of patients without co-amplification of topoisomerase 2 (TOPO-2), the arm without trastuzumab (ACT) showed a DFS significantly poorer that in the other arms; moreover, if we consider the lower toxicity of TCH regimen in comparison with anthracycline-containing arms, the innovative statements offered by BCIRG 006 trial appear evident, and these findings opened an important question about the consolidated employment of anthracyclines in adjuvant setting.The FinHer trial was a small trial testing a short course of trastuzumab (9 weeks) concomitantly with a chemotherapy including docetaxel, and there was a significant advantage in DFS for the trastuzumab based arms, without relevant toxicity and without any cardiotoxicity. Although data from all trastuzumab adjuvant trials, and without particulary from BCIRG-006 and FinHer trials, appear very intriguing, further follow-up is required.
Published: 2008

26. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].

Author: Fattoruso SI, Visca P, and Lopez M
Subjects: Antineoplastic Agents therapeutic use, Benzamides, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 22, Collagen Type I genetics, Collagen Type I, alpha 1 Chain, Dermatofibrosarcoma diagnosis, Evidence-Based Medicine, Humans, Imatinib Mesylate, Mohs Surgery methods, Piperazines therapeutic use, Prognosis, Pyrimidines therapeutic use, Radiotherapy, Adjuvant, Receptors, Platelet-Derived Growth Factor genetics, Risk Factors, Sex Distribution, Skin Neoplasms diagnosis, Treatment Outcome, Dermatofibrosarcoma genetics, Dermatofibrosarcoma therapy, Skin Neoplasms genetics, Skin Neoplasms therapy
Abstract: Dermatofibrosarcoma protuberans (DFSP) is a cutaneous low-grade malignancy with a high recurrence rate that rarely generates distant metastases. In most cases this tumor is associated with a chromosomal translocation involving the COL1A1 gene on chromosome 17 and the platelet-derived-growth-factor B gene on chromosome 22, generating a fusion gene that constitutively activates the PDGF receptor (PDG-FR). In the early stages of disease traditional surgery (wide excision) or Mohs micrographic surgery represent the standard of care. When surgical margins are positive, postoperative radiotherapy is a valuable option. Recently it has been shown that inhibiting PDGFR with imatinib can induce a high response rates in case of unresectable or metastatic disease. This targeted agent now represents the therapy of choice of advanced DFSP and it is the fi rst great therapeutic success in this disease after unsuccessful years using cytotoxic drugs. It is likely that a better knowledge of molecular biology of DFSP could, as it was the case for GISTs, may improve treatment results leading to the development of new targeted agents.
Published: 2008

27. [Development of docetaxel in the adjuvant chemotherapy of breast cancer].

Author: Fattoruso SI, Rossi S, Di Lauro L, Botti C, Vici P, and Lopez M
Subjects: Antineoplastic Agents adverse effects, Clinical Trials as Topic, Docetaxel, Evidence-Based Medicine, Female, Humans, Randomized Controlled Trials as Topic, Taxoids adverse effects, Treatment Outcome, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant, Taxoids therapeutic use
Abstract: The development of taxanes in cancer chemotherapy required several decades of research mainly because of the difficulty related to supply and formulation of paclitaxel. Lesser difficulty was encountered in the development of docetaxel, which initially took place in breast cancer. In this disease, docetaxel showed a significant activity, probably superior to that of paclitaxel. In the first-generation studies in patients with early breast cancer, comparing anthracycline-based regimens with regimens containing anthracyclines and taxanes, docetaxel significantly improved survival independently from schedule, either sequential or concurrent. The aim of current second-generation studies, comparing taxanes in all study arms, is to answer several questions, including the best administration schedule and the best taxane to be used. Currently, the use of docetaxel in the adjuvant chemotherapy of breast cancer represents one of the most important achievements in the treatment of this disease. However, since further improvement in therapeutic results are needed, it is likely that in the future docetaxel will be used in combination with molecular targeted agents.
Published: 2008

28. [A step foward in the treatment of GIST].

Author: Fattoruso SI and Lopez M
Subjects: Antineoplastic Agents administration & dosage, Benzamides, Gastrointestinal Stromal Tumors enzymology, Gastrointestinal Stromal Tumors genetics, Gastrointestinal Stromal Tumors surgery, Humans, Imatinib Mesylate, Neoplasm Proteins antagonists & inhibitors, Piperazines administration & dosage, Proto-Oncogene Proteins c-kit drug effects, Pyrimidines administration & dosage, Randomized Controlled Trials as Topic statistics & numerical data, Antineoplastic Agents therapeutic use, Gastrointestinal Stromal Tumors drug therapy, Piperazines therapeutic use, Pyrimidines therapeutic use
Published: 2008

29. [Target selectivity of anticancer drugs].

Author: Fattoruso SI, Di Lauro L, Conti F, Amodio A, and Lopez M
Subjects: Antineoplastic Agents pharmacokinetics, Humans, Neoplasms genetics, Neoplasms metabolism, Tissue Distribution, Antineoplastic Agents administration & dosage, Drug Delivery Systems, Neoplasms drug therapy
Abstract: Since the first use of chemotherapy, many efforts were devoted to develop drugs with a specific anticancer activity. Nevertheless, although several approaches to this end were used leading to significant results in cancer treatment, chemotherapy has mainly a palliative effect. The remarkable scientific advances in the knowledge of molecular changes in neoplastic diseases brought to development of new drugs with a specific molecular target. In some cases, this approach against a single molecular target, has been extremely successful, like imatinib in GIST. However, since in most cases tumor growth involves multiple genetic changes, it seems more appropriate to develop multitargeted agents. A successful way to improve target selectivity of anticancer drugs and to better choose patients to treat could be the use phase 0 clinical trials. In the future, the hope is to discover all genetic changes in each cancer patient and to restore the normal function of the cell with the aid of more advanced technologies.
Published: 2008

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

29 results on '"Fattoruso, S."'

1. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.

2. Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy

3. ITALIAN CANCER FIGURES - REPORT 2015: The burden of rare cancers in Italy = I TUMORI IN ITALIA - RAPPORTO 2015: I tumori rari in Italia

4. Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening [Caratteristiche dei tumori del colon retto diagnosticati in Italia nei primi anni Duemila. Dati dello studio IMPATTO sdelo screening colorettale]

5. I TUMORI IN ITALIA - RAPPORTO 2013: Tumori multipli = ITALIAN CANCER FIGURES - REPORT 2013: Multiple tumours

6. Evaluation of diagnostic investigations used in breast cancer patients resident in Latina province during three years follow up after diagnosis

7. Italian cancer figures, report 2012: Cancer in children and adolescents

8. R40 - Evaluation of diagnostic investigations used in breast cancer patients resident in Latina province during three years follow up after diagnosis

9. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines

10. Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study

11. Italian cancer figures, report 2012: Cancer in children and adolescents

12. Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

13. Fiberoptic bronchoscopy as diagnostic tool in primitive lung cancer,Ruolo diagnostico della fibrobroncoscopia nelle neoplasie polmonari primitive

14. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment

15. Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer,Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo

16. Development of docetaxel in the adjuvant chemotherapy of breast cancer,Sviluppo del docetaxel nella chemioterapia adiuvante del cancro della mammella

17. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients

18. Real-Time Obstacle Detection and Field Mapping System Using LIDAR-ToF Sensors for Small UAS

19. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.

20. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.

21. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

22. [Fiberoptic bronchoscopy as diagnostic tool in primitive lung cancer].

23. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.

24. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].

25. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.

26. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].

27. [Development of docetaxel in the adjuvant chemotherapy of breast cancer].

28. [A step foward in the treatment of GIST].

29. [Target selectivity of anticancer drugs].

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

29 results on '"Fattoruso, S."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources